Peer-reviewedCC BYFrontiers in immunology
FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort
- 1Department of General Surgery, Lanzhou University Second Hospital , ,
Related
- A pretreatment hormonal-nutritional-immune score for locally advanced gastric cancer receiving neoadjuvant immunochemotherapy: a multicenter retrospective cohort study
- Genomic epidemiology of blaCTX−M−65-positive clinical Enterobacteriaceae reveals clonal diversity and shared plasmid backbones
- Commentary: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity
- Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures
- 523 Lymphaticsparing neoadjuvant SABR and pembrolizumab (neo-ImmunoSABR) in HPVnegative HNSCC: results from a phase II multi-center trial with immune correlates
BibTeX
@article{liu2026flot,
title = {{FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort}},
author = {Penghui Liu and Na Li and Jiwu Guo and Jizhen Wang and Ziyuan Mou and Jie Mao},
journal = {Frontiers in immunology},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13658598},
note = {CC BY},
}
RIS
TY - JOUR
TI - FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort
AU - Penghui Liu
AU - Na Li
AU - Jiwu Guo
AU - Jizhen Wang
AU - Ziyuan Mou
AU - Jie Mao
PY - 2026
DA - 2026/10/16
JO - Frontiers in immunology
UR - https://europepmc.org/article/PMC/PMC13658598
SN - 1664-3224
ER -